DGIdb - IL2RA Gene Record

IL2RA 3559 Druggable Genome

Alternate Names:

3559
INTERLEUKIN 2 RECEPTOR SUBUNIT ALPHA
IL2RA
CD25
IDDM10
IL2R
IMD41
TCGFR
p55
147730
6008
ENSG00000134460
OTTHUMG00000017616
P01589
IL2RA_HUMAN
IL-2 receptor subunit alpha
CD_antigen=CD25
TAC antigen
Interleukin-2 receptor subunit alpha
IL-2R subunit alpha
IL-2-RA
IL2-RA
P42701
IL12RB1
PA29828
Interleukin 2 receptor
T20710
Interleukin 2 receptor alpha
T03313

Gene Info:

Target Class	Receptors
Target Subclass	Receptor
Target Subclass	Type 1 cytokine receptor
Target Subclass	CytokineR
Target Main Class	Receptors
Transmembrane Helix Count	1
Target Subclass	IG
Target Subclass	Type1
Gene Biotype	PROTEIN_CODING

(9 More Sources)

Gene Categories: Category Details

EXTERNAL SIDE OF PLASMA MEMBRANE
DRUGGABLE GENOME

Publications:

Garcia et al., Plasmapheresis for recurrent posttransplant focal segmental glomerulosclerosis., Transplant. Proc.
Monti et al., 2009, Disengaging the IL-2 receptor with daclizumab enhances IL-7-mediated proliferation of CD4(+) and CD8(+) T cells., Am. J. Transplant.
Shamsi et al., 2005, Allogeneic peripheral blood stem cell transplant (PBSCT) using anti-IL2 receptor antibody Daclizumab for the prevention of acute graft versus host disease in steroid refractory Diamond Blackfan anaemia: a case report., J Pak Med Assoc
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Krouwels et al., 1996, Glucocorticosteroids affect functions of airway- and blood-derived human T-cell clones, favoring the Th1 profile through two mechanisms., Am. J. Respir. Cell Mol. Biol.
Przepiorka et al., 2000, Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease., Blood
Patlolla et al., 2007, Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation., Am. J. Transplant.
Dornand et al., 1992, Contrasting effects of the protein kinase C inhibitor staurosporine on the interleukin-1 and phorbol ester activation pathways in the EL4-6.1 thymoma cell line., J. Cell. Physiol.
Elias et al., 1993, Effect of propylthiouracil and methimazole on serum levels of interleukin-2 receptors in patients with psoriasis., Int. J. Dermatol.
Gessl et al., 1995, Activated naive CD4+ peripheral blood T cells in autoimmune thyroid disease., Thyroid
Balázs, 1991, Increased level of soluble interleukin-2 receptor in sera of patients with Graves' disease., Biomed. Pharmacother.
Liu et al., 1998, Similarities between the sensitivity to 2-chlorodeoxyadenosine of lymphocytes from CLL patients and bryostatin 1-treated WSU-CLL cells: an infrared spectroscopic study., Cancer Lett.
Kovarik et al., 1998, Disposition and immunodynamics of basiliximab in liver allograft recipients., Clin. Pharmacol. Ther.
Berard et al., 1999, A review of interleukin-2 receptor antagonists in solid organ transplantation., Pharmacotherapy
Choy et al., 2003, IL2-receptor antagonist (basiliximab) induction therapy is associated with lower morbidity and mortality in renal transplant recipients., Transplant. Proc.
Mentré et al., 1999, Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: an application to basiliximab in renal transplantation., J Pharmacokinet Biopharm
Messingham et al., 2001, Testosterone receptor blockade restores cellular immunity in male mice after burn injury., J. Endocrinol.
Nakase et al., 1997, Clinical importance of interleukin-2 receptor alpha-chain expression in acute leukemia. The Japan Cooperative Group of Leukemia/Lymphoma., Cancer Detect. Prev.
Bleeker et al., T-cell evaluation in patients with colon cancer: dinitrochlorobenzene skin testing versus plasma levels of sIL-2r and sCD8., Ann. Surg. Oncol.
Liu et al., 2006, [Screening of short peptides binding to cell surface interleukin-2 receptor alpha chain]., Nan Fang Yi Ke Da Xue Xue Bao
Ouyang et al., 1999, Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes., Arch. Toxicol.
Recchia et al., 2003, Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy., J. Exp. Clin. Cancer Res.
Waldmann, 2007, Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma., Oncogene
Waldmann, 2007, Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey., J. Clin. Immunol.
Vlad et al., 2007, Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation., Transpl. Immunol.
Sugita et al., 1992, [Analysis of lymphocyte surface markers in childhood acute lymphoblastic leukemia during maintenance chemotherapy]., Gan To Kagaku Ryoho
Kos et al., 2000, Protective role of IL-2 during activation of T cells with bryostatin 1., Int. J. Immunopharmacol.
Mantzavinos et al., 1996, Serum markers of immune activation in women undergoing in-vitro fertilization and embryo transfer., Hum. Reprod.
Attanasio et al., 2002, Immunomodulatory effects of estrogen and progesterone replacement in a nonhuman primate model., J. Clin. Immunol.
Goebel et al., 2006, Tubulin polymerization modulates interleukin-2 receptor signal transduction in human T cells., J. Recept. Signal Transduct. Res.
Balaji et al., 1997, Effect of 5-fluorouracil on interleukin-1 and interleukin-2 receptor expression., Biochem. Mol. Biol. Int.
Wan, 1998, [Effects of lentinan of peripheral blood mononuclear cell expression of interleukin-2 receptor in patients with chronic hepatitis B in vivo and in vitro]., Hunan Yi Ke Da Xue Xue Bao
Zwirska-Korczala et al., 2004, Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders., J Clin Pharm Ther
Walz et al., 1989, Similar effects of cyclosporine and verapamil on lymphokine, interleukin 2 receptor, and proto-oncogene expression., Transplantation
Goebel et al., 2005, Atorvastatin affects interleukin-2 signaling by altering the lipid raft enrichment of the interleukin-2 receptor beta chain., J. Investig. Med.
Duvic et al., 2008, Optimizing denileukin diftitox (Ontak) therapy., Future Oncol
Kiyokawa et al., 1989, Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia., Cancer Res.
Turturro, 2007, Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders., Expert Rev Anticancer Ther
Murphy et al., 1988, Interleukin 2 toxin: a step toward selective immunomodulation., Am. J. Kidney Dis.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Colić et al., 2000, Garlic extracts stimulate proliferation of rat lymphocytes in vitro by increasing IL-2 and IL-4 production., Immunopharmacol Immunotoxicol
Hancock et al., 1988, Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptor on human mononuclear phagocytes by induction of prostaglandin E., J. Immunol.
Forrest et al., 2005, Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?, Transpl. Immunol.
Caproni et al., 1995, Pharmacologic modulation by cetirizine of some adhesion molecules expression in psoriatic skin lesions., Int. J. Dermatol.
Reddy et al., 1991, Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2',3'-dideoxyinosine (ddI)., J. Clin. Lab. Anal.

BASILIXIMAB IL2RA

Interaction Score: 7.11

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

Trial Name basiliximab,Simulect

PMIDs:
9695721 10512062 12591363 16908318 11752352 10567956

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
ALDESLEUKIN IL2RA

Interaction Score: 5.33

Interaction Types & Directionality:

agonist (activating)

modulator

Interaction Info:

Novel drug target Established target

Trial Name Proleukin IL-2

Mechanism of Interaction Interleukin-2 receptor agonist

PMIDs:
16864089 10207608 16767920 11752352 17530023 17216565 17584597

Sources:
TdgClinicalTrial ChemblInteractions TEND
DACLIZUMAB IL2RA

Interaction Score: 5.33

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

Novel drug target Established target

PMIDs:
16908318 19788505 16304857 11752352 8600944 10607689 17564638

Sources:
TdgClinicalTrial ChemblInteractions TEND
DENILEUKIN DIFTITOX IL2RA

Interaction Score: 4.26

Interaction Types & Directionality:

binder

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor binding agent

Direct Interaction yes

PMIDs:
18684057 2786749 17187516 3124610 11752352 17016423 17139284

Sources:
ChemblInteractions
LENTINAN IL2RA

Interaction Score: 4.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10681809

Sources:
NCI
DINITROCHLOROBENZENE IL2RA

Interaction Score: 4.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9607619

Sources:
NCI
LMB-2 IL2RA

Interaction Score: 4.26

Interaction Types & Directionality:

n/a

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Interleukin-2 receptor alpha chain binding agent

PMIDs:
None found

Sources:
ChemblInteractions TTD
INOLIMOMAB IL2RA

Interaction Score: 4.26

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Interleukin-2 receptor alpha chain antagonist

PMIDs:
None found

Sources:
ChemblInteractions TTD
CETIRIZINE IL2RA

Interaction Score: 0.85

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7591422

Sources:
NCI
METHIMAZOLE IL2RA

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8340196 7647571 1760523

Sources:
NCI
GARLIC IL2RA

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10737264

Sources:
NCI
DECITABINE IL2RA

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15814281

Sources:
NCI
DIDANOSINE IL2RA

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1774603

Sources:
NCI
THYROXINE IL2RA

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15068404

Sources:
NCI
BRYOSTATIN IL2RA

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10988359

Sources:
NCI
METHYLPREDNISOLONE IL2RA

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8981122

Sources:
NCI
CLADRIBINE IL2RA

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9619876

Sources:
NCI
PROPYLTHIOURACIL IL2RA

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8340196

Sources:
NCI
ALDESLEUKIN IL2RA

Interaction Score: 0.25

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name IRX-2

Novel drug target Established target

PMIDs:
9167045

Sources:
TdgClinicalTrial NCI
FLUTAMIDE IL2RA

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11312147

Sources:
NCI
THEOPHYLLINE IL2RA

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3129507

Sources:
NCI
CAFFEINE IL2RA

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3129507

Sources:
NCI
STAUROSPORINE IL2RA

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1560050

Sources:
NCI
VERAPAMIL IL2RA

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2645720

Sources:
NCI
MERCAPTOPURINE IL2RA

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1580639

Sources:
NCI
ATORVASTATIN IL2RA

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16207471

Sources:
NCI
PROGESTERONE IL2RA

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12405159

Sources:
NCI
PACLITAXEL IL2RA

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16595340

Sources:
NCI
FLUOROURACIL IL2RA

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9238541

Sources:
NCI

Ensembl: ENSG00000134460
- Version: 101_38
Alternate Names:

IL2RA Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: P42701
- Version: January-2014
Alternate Names:

IL12RB1 Gene Symbol

IL2RA Gene Symbol

Gene Info:

Target Class Receptors

Target Subclass Receptor

Target Subclass Type 1 cytokine receptor

Publications:
TEND: P01589
- Version: 01-August-2011
Alternate Names:

P01589 Uniprot Accession

3559 Entrez Gene Id

IL2RA Gene Symbol

Gene Info:

Target Subclass CytokineR

Target Main Class Receptors

Transmembrane Helix Count 1

Publications:
TdgClinicalTrial: P01589
- Version: January-2014
Alternate Names:

IL2RA Gene Symbol

Gene Info:

Target Class Receptors

Target Subclass Receptor

Target Subclass Type 1 cytokine receptor

Publications:

NCI: IL2RA

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Dornand et al., 1992, Contrasting effects of the protein kinase C inhibitor staurosporine on the interleukin-1 and phorbol ester activation pathways in the EL4-6.1 thymoma cell line., J. Cell. Physiol.

Messingham et al., 2001, Testosterone receptor blockade restores cellular immunity in male mice after burn injury., J. Endocrinol.

Bleeker et al., T-cell evaluation in patients with colon cancer: dinitrochlorobenzene skin testing versus plasma levels of sIL-2r and sCD8., Ann. Surg. Oncol.

ChemblInteractions: IL2RA
- Version: chembl_23
Alternate Names:

p55 UNIPROT

IL2RA GENE_SYMBOL

Interleukin-2 receptor subunit alpha UNIPROT

Gene Info:

Publications:
HingoraniCasas: ENSG00000134460
- Version: 31-May-2017
Alternate Names:

ENSG00000134460 Gene Symbol

IL2RA Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
PharmGKB: IL2RA
- Version: 18-August-2020
Alternate Names:

PA29828 PharmGKB ID

Gene Info:

Publications:
Tempus: IL2RA
- Version: 11-November-2018
Alternate Names:

IL2RA Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
TTD: Interleukin 2 receptor
- Version: 2020.06.01
Alternate Names:

IL2R TTD Gene Abbreviation

T20710 TTD Target ID

Gene Info:

Publications:
TTD: Interleukin 2 receptor alpha
- Version: 2020.06.01
Alternate Names:

IL2RA TTD Gene Abbreviation

T03313 TTD Target ID

Gene Info:

Publications:
FDA: IL2RA
- Version: 04-September-2020
Alternate Names:

Gene Info:

Publications:
GO: IL2RA
- Version: 01-February-2022
Alternate Names:

Gene Info:

Gene Categories:

EXTERNAL SIDE OF PLASMA MEMBRANE

Publications:

Mechanism of Interaction	Interleukin-2 receptor inhibitor
Direct Interaction	yes
Trial Name	basiliximab,Simulect

Novel drug target	Established target
Trial Name	Proleukin IL-2
Mechanism of Interaction	Interleukin-2 receptor agonist

Mechanism of Interaction	Interleukin-2 receptor binding agent
Direct Interaction	yes

Direct Interaction	yes
Mechanism of Interaction	Interleukin-2 receptor alpha chain binding agent

Direct Interaction	yes
Mechanism of Interaction	Interleukin-2 receptor alpha chain antagonist

p55	UNIPROT
IL2RA	GENE_SYMBOL
Interleukin-2 receptor subunit alpha	UNIPROT

antibody (inhibitory)
inhibitor (inhibitory)

agonist (activating)
modulator

antibody (inhibitory)
inhibitor (inhibitory)

IL2RA Gene Record

IL2RA 3559 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Interleukin-2 receptor inhibitor Direct Interaction yes Trial Name basiliximab,Simulect

PMIDs: 9695721 10512062 12591363 16908318 11752352 10567956

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: agonist (activating) modulator

Interaction Info: Novel drug target Established target Trial Name Proleukin IL-2 Mechanism of Interaction Interleukin-2 receptor agonist

PMIDs: 16864089 10207608 16767920 11752352 17530023 17216565 17584597

Sources: TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Interleukin-2 receptor inhibitor Direct Interaction yes Novel drug target Established target

PMIDs: 16908318 19788505 16304857 11752352 8600944 10607689 17564638

Sources: TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality: binder

Interaction Info: Mechanism of Interaction Interleukin-2 receptor binding agent Direct Interaction yes

PMIDs: 18684057 2786749 17187516 3124610 11752352 17016423 17139284

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10681809

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9607619

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Direct Interaction yes Mechanism of Interaction Interleukin-2 receptor alpha chain binding agent

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Interleukin-2 receptor alpha chain antagonist

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7591422

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8340196 7647571 1760523

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10737264

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15814281

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1774603

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15068404

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10988359

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8981122

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9619876

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8340196

Sources: NCI

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name IRX-2 Novel drug target Established target

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

Trial Name basiliximab,Simulect

PMIDs:
9695721 10512062 12591363 16908318 11752352 10567956

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

agonist (activating)

modulator

Interaction Info:

Novel drug target Established target

Trial Name Proleukin IL-2

Mechanism of Interaction Interleukin-2 receptor agonist

PMIDs:
16864089 10207608 16767920 11752352 17530023 17216565 17584597

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

Novel drug target Established target

PMIDs:
16908318 19788505 16304857 11752352 8600944 10607689 17564638

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

binder

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor binding agent

Direct Interaction yes

PMIDs:
18684057 2786749 17187516 3124610 11752352 17016423 17139284

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
10681809

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9607619

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Interleukin-2 receptor alpha chain binding agent

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Interleukin-2 receptor alpha chain antagonist

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

n/a

PMIDs:
7591422

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8340196 7647571 1760523

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10737264

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15814281

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
1774603

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15068404

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10988359

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8981122

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9619876

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8340196

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name IRX-2

Novel drug target Established target

PMIDs:
9167045

Sources:
TdgClinicalTrial NCI

Interaction Types & Directionality:

n/a

PMIDs:
11312147

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
3129507

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
3129507

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
1560050

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
2645720

Sources:
NCI

Interaction Types & Directionality:

n/a